Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging trial of PF-06651600 and PF-06700841 in moderate to severe ulcerative colitis
MOH_2017-10-04_000837Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PF-06651600 or placebo with PF-06700841 or placebo (2 arms). Started May 2017; status: recruiting.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-10-04_000837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-04_000837.